Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Bestmade Natural Products Ferr Phos
Generic Name
Ferr Phos
Active Ingredient
Ferric PyrophosphateCategory
Other
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 6 [hp_X]/6[hp_X] | TABLET, SOLUBLE | ORAL | 82969-1004 |
Detailed information about Bestmade Natural Products Ferr Phos
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Bestmade Natural Products Ferr Phos, you must consult a qualified healthcare professional.
Ferric Pyrophosphate is a specialized iron replacement product primarily used to maintain hemoglobin levels in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). It belongs to the iron supplement class and is uniquely delivered via hemodialysate.
The dosing of Ferric Pyrophosphate is unique because it is not based on a 'mg/kg' body weight formula but rather on the concentration within the hemodialysate fluid.
As of 2026, the safety and effectiveness of Ferric Pyrophosphate have not been established in pediatric patients. Clinical trials have primarily focused on the adult population (18 years and older). Consequently, healthcare providers generally avoid using this specific iron delivery system in children unless part of a controlled clinical study.
Because Ferric Pyrophosphate is specifically indicated for patients with end-stage renal disease (ESRD) on hemodialysis, no dosage adjustment is required for renal impairment. The drug is designed to work within the parameters of failing kidneys.
There are no specific dosage adjustments provided for patients with liver disease. However, because the liver is the primary site for iron storage (as ferritin), patients with severe hepatic impairment should be monitored closely for signs of iron overload.
Clinical studies included a significant number of patients aged 65 and over. No overall differences in safety or effectiveness were observed between these patients and younger patients. Dosage remains consistent with the standard adult protocol.
Patients do not 'take' Ferric Pyrophosphate in the traditional sense. It is administered by dialysis nurses or technicians.
If a dialysis session is missed, the dose of Ferric Pyrophosphate associated with that session is also missed. Because this medication is used for maintenance, missing a single dose is usually not a medical emergency, but it may lead to a gradual decline in iron stores over time. Your healthcare provider will resume administration at your next scheduled dialysis appointment.
An acute overdose of Ferric Pyrophosphate is unlikely because the delivery rate is limited by the dialysis machine's flow rate. However, chronic over-administration can lead to hemosiderosis (excessive accumulation of iron in the tissues).
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Regular blood tests are required to ensure your iron levels remain within the target range.
In clinical trials (such as the CRUISE trials), Ferric Pyrophosphate was generally well-tolerated, but some side effects occurred frequently. It is often difficult to distinguish side effects of the drug from the symptoms of dialysis itself.
> Warning: Stop taking Ferric Pyrophosphate and call your doctor immediately if you experience any of these.
The primary concern with long-term use of any iron product is hemosiderosis. This is the deposition of iron in vital organs such as the liver, heart, and pancreas. Over many years, this can lead to organ dysfunction, including cirrhosis or heart failure. To prevent this, healthcare providers perform regular blood tests to check 'ferritin' and 'transferrin saturation' (TSAT). If these levels become too high, Ferric Pyrophosphate treatment is temporarily paused.
No FDA black box warnings for Ferric Pyrophosphate. Unlike some other IV iron products (such as Iron Dextran) which carry black box warnings for fatal anaphylactic-type reactions, Ferric Pyrophosphate has a cleaner safety profile in this regard. However, the standard precautions for iron administration still apply.
Report any unusual symptoms to your healthcare provider. Your dialysis team is trained to manage these side effects during your treatment sessions.
Ferric Pyrophosphate is a potent medical agent that must be used only in the specific clinical setting of hemodialysis. It is not a general-purpose iron supplement. Patients must be aware that while this drug helps manage anemia, it requires constant clinical oversight. The most critical safety aspect is the maintenance of iron balance; both too little and too much iron can be harmful to patients with kidney disease.
No FDA black box warnings for Ferric Pyrophosphate.
To ensure safety and efficacy, the following laboratory tests are mandatory for patients receiving Ferric Pyrophosphate:
Ferric Pyrophosphate can cause hypotension (low blood pressure) and dizziness. Patients should not drive or operate heavy machinery immediately following a dialysis session until they are certain they are not experiencing these side effects. The 'post-dialysis fatigue' often experienced by patients can be compounded by the medication.
There is no direct chemical interaction between Ferric Pyrophosphate and alcohol. However, alcohol can affect blood pressure and hydration status, both of which are critical for dialysis patients. Patients should discuss their alcohol consumption with their nephrologist (kidney doctor).
If Ferric Pyrophosphate is discontinued, the patient will stop receiving the 5-7 mg of iron typically lost during dialysis. Over time, this will likely lead to a depletion of iron stores and a drop in hemoglobin levels unless an alternative iron source (like IV iron) is started. There is no 'withdrawal syndrome' associated with stopping this medication, but the underlying anemia will likely worsen.
> Important: Discuss all your medical conditions with your healthcare provider before starting Ferric Pyrophosphate. Provide a full list of all medications you are currently taking, including over-the-counter drugs.
There are no absolute 'contraindicated' drug combinations in the sense of a fatal chemical reaction. However, the following should be avoided:
Because Ferric Pyrophosphate is delivered directly into the blood via the dialysis machine, food does not affect its absorption. There are no restrictions on grapefruit, dairy, or high-fat meals specifically related to this medication. However, patients must still follow the strict 'renal diet' (low potassium, low phosphorus) prescribed by their dietitian.
For each major interaction, the management strategy is usually 'monitor and adjust.' The nephrology team will balance the iron delivery with the patient's ESA requirements and current iron stores.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even 'natural' products can interfere with the complex chemistry of dialysis.
Ferric Pyrophosphate must NEVER be used in the following circumstances:
These conditions require a careful risk-benefit analysis by the nephrologist:
There is little evidence of cross-sensitivity between Ferric Pyrophosphate and other iron salts (like Ferric Gluconate or Iron Sucrose) because the chemical structure of the pyrophosphate-citrate ligand is unique. However, patients who have reacted to other IV irons should be monitored with extreme caution during their first several sessions with Ferric Pyrophosphate.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to iron injections, before prescribing Ferric Pyrophosphate.
There are no adequate and well-controlled studies of Ferric Pyrophosphate in pregnant women. In animal studies, no evidence of harm to the fetus was found at doses significantly higher than the human maintenance dose. However, because iron requirements change during pregnancy and hemodialysis itself carries high risks for the pregnancy, this drug should only be used if the potential benefit justifies the potential risk to the fetus. It is generally not the first-line choice for iron deficiency in pregnancy unless the mother is already on stable hemodialysis.
It is not known whether the iron from Ferric Pyrophosphate is excreted in human milk. However, iron is a normal component of breast milk. The citrate and pyrophosphate components are also naturally occurring. The risk to a nursing infant is considered low, but mothers should consult their healthcare provider. The primary concern is the mother's health and her ability to maintain stable hemoglobin levels while nursing.
Ferric Pyrophosphate is not approved for use in patients under the age of 18. The safety profile, particularly regarding long-term iron deposition in growing tissues and the effect on growth plates, has not been established. Pediatric dialysis patients are typically managed with weight-based IV iron dosing rather than dialysate-based delivery.
Clinical trials included a large proportion of patients over age 65. No specific 'geriatric syndrome' or increased risk profile was identified for this age group. However, elderly patients are more prone to intradialytic hypotension (blood pressure drops during dialysis). Since Ferric Pyrophosphate can also cause hypotension, the dialysis team must monitor the ultrafiltration rate and blood pressure closely in older adults to prevent falls or fainting after the session.
As this drug is specifically for patients with Stage 5 Chronic Kidney Disease (End-Stage Renal Disease) on dialysis, no adjustments are needed for the 'impairment' itself. It is the only population for which the drug is intended. It is not studied or recommended for patients with Stage 1-4 CKD.
No formal studies have been conducted in patients with hepatic impairment. Because the liver stores iron as ferritin, patients with Child-Pugh Class B or C cirrhosis should be monitored for signs of iron overload more frequently (e.g., monthly ferritin checks) than the standard population.
> Important: Special populations require individualized medical assessment. Always inform your nephrologist if you are planning to become pregnant or are currently breastfeeding.
Ferric Pyrophosphate Citrate is a complex of iron (III), citrate, and pyrophosphate. Its mechanism of action is unique in the world of iron replacement therapy. When added to the dialysate, the iron (III) ions are kept in a soluble, non-reactive state by the citrate and pyrophosphate ligands. As the dialysate passes through the dialyzer, the iron molecules diffuse across the semi-permeable membrane into the patient's blood.
Once in the blood, the iron is immediately transferred to transferrin, the body's primary iron transport protein. This 'direct-to-transferrin' delivery is the key pharmacological advantage. Traditional IV iron products consist of iron cores surrounded by carbohydrate shells (like sucrose or dextran). These large complexes must be engulfed by macrophages in the reticuloendothelial system (RES), where the iron is processed and eventually released. Ferric Pyrophosphate bypasses this step, providing a more 'physiologic' delivery that matches the rate of iron loss during dialysis.
| Parameter | Value |
|---|---|
| Bioavailability | 100% (via dialyzer transfer) |
| Protein Binding | >99% (to Transferrin) |
| Half-life | Linked to RBC lifespan (~120 days) |
| Tmax | End of dialysis session (3-4 hours) |
| Metabolism | Not metabolized by CYP enzymes |
| Excretion | Minimal (Iron is recycled by the body) |
Ferric Pyrophosphate is classified as an Iron Replacement Product. Within this class, it is specifically categorized as a Dialysate-Delivered Iron Supplement. It is currently the only FDA-approved medication in this specific sub-class, distinguishing it from IV iron salts and oral iron supplements.
Common questions about Bestmade Natural Products Ferr Phos
Ferric Pyrophosphate is specifically used to maintain iron levels and hemoglobin in adult patients who are undergoing regular hemodialysis for chronic kidney disease. During dialysis, patients naturally lose a small amount of blood and iron, which can lead to anemia over time. This medication is added to the dialysis fluid (dialysate) to replace that lost iron during every treatment session. It helps ensure that the bone marrow has enough iron to produce healthy red blood cells. It is not used for patients who are not on dialysis or for those with simple iron deficiency that can be treated with pills.
The most common side effect reported by patients is hypotension, which is a drop in blood pressure that can cause dizziness or lightheadedness during dialysis. Other frequent side effects include headaches, muscle cramps (often in the legs), and swelling in the ankles or hands (peripheral edema). Some patients also report feeling nauseated or having a mild fever after their treatment. Because these symptoms are also common in dialysis patients not taking the drug, it is important to discuss any new or worsening symptoms with your dialysis nurse. Most side effects are mild and can be managed by adjusting the dialysis settings.
There is no known direct chemical interaction between Ferric Pyrophosphate and alcohol. However, alcohol can cause dehydration and can interfere with blood pressure regulation, both of which are significant concerns for patients with kidney failure on dialysis. Drinking alcohol can make the common side effect of hypotension (low blood pressure) much worse. Most nephrologists recommend strictly limiting alcohol intake to maintain overall health and fluid balance. Always consult your doctor before consuming alcohol to ensure it is safe for your specific stage of kidney disease.
The safety of Ferric Pyrophosphate during pregnancy has not been established through large-scale clinical trials in humans. While animal studies did not show direct harm to the developing fetus, the risks of hemodialysis itself during pregnancy are very high. Doctors generally only use this medication in pregnant women if the benefits of maintaining hemoglobin clearly outweigh the unknown risks to the baby. If you are pregnant or planning to become pregnant while on dialysis, your medical team will create a specialized care plan. They may choose to use more established iron treatments that have more data in pregnant populations.
Ferric Pyrophosphate begins working immediately as soon as the dialysis session starts, as iron begins crossing into your bloodstream right away. However, you will not 'feel' the effects instantly. It takes time for the bone marrow to use that iron to build new red blood cells. Most patients see a stabilization or improvement in their hemoglobin levels after several weeks of consistent treatment (usually 3 to 4 weeks). Your doctor will monitor your blood work monthly to see how well the medication is maintaining your iron stores. It is a maintenance therapy, meaning it is designed for long-term stability rather than a quick fix.
Since Ferric Pyrophosphate is administered by your clinical team during your dialysis sessions, 'stopping' it usually means the doctor has decided to pause the treatment. There is no physical withdrawal syndrome or danger in stopping the drug suddenly. However, because you lose iron during every dialysis session, stopping the medication will eventually lead to iron deficiency and a drop in your hemoglobin levels. This can make you feel more tired, short of breath, and weak. If you have concerns about the medication, discuss them with your nephrologist rather than simply skipping dialysis sessions.
A missed dose of Ferric Pyrophosphate usually occurs if you miss a scheduled hemodialysis session. If this happens, you should contact your dialysis center immediately to reschedule your treatment. Missing one dose of iron is generally not a medical emergency, but missing the dialysis session itself is very dangerous. The iron maintenance will simply resume at your next treatment. Your clinical team tracks your total iron intake, so they will be aware of the missed dose and will adjust your future treatments or blood tests accordingly to ensure your levels remain stable.
Ferric Pyrophosphate does not directly cause weight gain or increase body fat. However, some patients may experience peripheral edema (swelling), which is the retention of fluid in the legs and arms. This fluid retention can show up as a higher number on the scale. It is important to distinguish between 'fluid weight' and 'actual weight' in dialysis patients. If you notice a sudden increase in weight or swelling, it usually means your fluid balance needs to be adjusted during your next dialysis session. Always report rapid weight changes to your dialysis team.
Ferric Pyrophosphate is generally safe to use alongside most medications common for kidney patients, such as blood pressure drugs and phosphate binders. However, it should not be used at the same time as other intravenous (IV) iron injections, as this could lead to dangerous iron overload. It also works in tandem with Erythropoiesis-Stimulating Agents (ESAs) like Epogen. Because Ferric Pyrophosphate makes ESAs more effective, your doctor might actually be able to lower your dose of those other medications. Always provide your full medication list to your nephrologist to check for specific interactions.
As of 2026, Ferric Pyrophosphate Citrate is primarily available under the brand name Triferic. While the chemical 'ferric pyrophosphate' has existed for a long time as a food additive, the specific 'citrate' formulation and the delivery system for dialysis are protected by patents. Generic versions may become available in the future as these patents expire. However, because it is a complex drug-device product (requiring specific mixing with dialysis concentrates), the FDA has strict requirements for any future generic versions to prove they work exactly the same way.
Other drugs with the same active ingredient (Ferric Pyrophosphate)